Syndromes, disorders and maternal risk factors associated with neural tube defects (IV)

Taiwanese Journal of Obstetrics and Gynecology

Volumn 47, Issue 2, 2008, Pages 141-150

  Chen, Chih Ping ^a,b,c,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Fetal; Maternal; Neural tube defects; Risk factors

Indexed keywords

AUTOANTIBODY; BETAINE HOMOCYSTEINE METHYLTRANSFERASE; CLOMIFENE; CYANOCOBALAMIN; DIHYDROFOLATE REDUCTASE; FOLATE RECEPTOR; FOLIC ACID; GLYCINE HYDROXYMETHYLTRANSFERASE; METHYLENETETRAHYDROFOLIC ACID; SUMO 1 PROTEIN; TERATOGENIC AGENT; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; CONFIDENCE INTERVAL; CYANOCOBALAMIN DEFICIENCY; DIHYDROFOLATE REDUCTASE RECEPTOR GENE; DNA POLYMORPHISM; FETUS RISK; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENE; GENETIC COUNSELING; HUMAN; INFERTILITY THERAPY; METHYLENESTETRAHYDROFOLATE REDUCTASE GENE; NEURAL TUBE DEFECT; REDUCED FOLATE CARRIER 1 GENE; REVIEW; RISK FACTOR; SERINE HYDROXYMETHYLTRANSFERASE GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THYMIDYLATE SYNTHASE PROMOTER ENHANCER REGION GENE;

EID: 48949118169     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60071-6     Document Type: Review

References (131)

1. Wu YW, Croen LA, Henning L, Najjar DV, Schembri M, Croughan MS. Potential association between infertility and spinal neural tube defects in offspring. Birth Defects Res A Clin Mol Teratol 2006;76:718-22.
2. Bánhidy F, Acs N, Czeizel AE. Ovarian cysts, clomiphene therapy, and the risk of neural tube defects. Int J Gynaecol Obstet 2008;100:86-8.
3. Lancaster PAL. Congenital malformations after in-vitro fertilisation. Lancet 1987;330:1392-3.
4. Cornel MC, Ten Kate LP, Dukes MNG, et al. Ovulation induction and neural tube defects. Lancet 1989;333:1386.
5. Cornel MC, Ten Kate LP, Te Meerman GJ. Ovulation induction, in-vitro fertilisation, and neural tube defects. Lancet 1989;334:1530.
6. Cuckle HS, Wald NJ. Ovulation induction and neural tube defects. Lancet 1989;334:1281.
7. Czeizel AE. Ovulation induction and neural tube defects. Lancet 1989;334:167.
8. Robert E, Pradat E, Laumon B. Ovulation induction and neural tube defects: a registry study. Reprod Toxicol 1991; 5:83-4.
9. Medveczky E, Puhó E, Czeizel EA. The use of drugs in mothers of offspring with neural-tube defects. Pharmacoepidemiol Drug Saf 2004;13:443-55.
10. Mills JL, Simpson JL, Rhoads GG, et al. Risk of neural tube defects in relation to maternal fertility and fertility drug use. Lancet 1990;336:103-4.
11. Van Loon K, Besseghir K, Eshkol A. Neural tube defects after infertility treatment: a review. Fertil Steril 1992;58:875-84.
12. Greenland S, Ackerman DL. Clomiphene citrate and neural tube defects: a pooled analysis of controlled epidemiologic studies and recommendations for future studies. Fertil Steril 1995;64:936-41.
13. Källén B, Olausson PO, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. Obstet Gynecol 2002; 100:414-9.
14. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002;346:725-30.
15. Kurinczuk JJ, Hansen M, Bower C. The risk of birth defects in children born after assisted reproductive technologies. Curr Opin Obstet Gynecol 2004;16:201-9.
16. Källén B, Finnström O, Nygren KG, Olausson PO. In vitro fertilization (IVF) in Sweden: risk for congenital malformations after different IVF methods. Birth Defects Res A Clin Mol Teratol 2005;73:162-9.
17. Olson CK, Keppler-Noreuil KM, Romitti PA, Budelier WT, Ryan G, Sparks AE, Van Voorhis BJ. In vitro fertilization is associated with an increase in major birth defects. Fertil Steril 2005;84:1308-15.
18. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
19. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
20. Czeizel AE. Folic acid and prevention of birth defects. JAMA 1996;275:1635-66.
21. Hall JG, Solehdin F. Genetics of neural tube defects. Merit Retard Dev Disabil Res Rev 1998;4:269-81.
22. Hibbard BM. The role of folic acid in pregnancy; with particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Commonw 1964;71:529-42.
23. Hibbard ED, Smithells RW. Folic acid metabolism and human embryopathy. Lancet 1965;285:1254.
24. Smithells RW, Sheppard S, Schorah CJ, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980;315:339-40.
25. Laurence KM, James N, Miller MH,Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 1981 ;282:1509-11.
26. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-5.
27. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989;150:613-9.
28. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, WillettW. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989;262:2847-52.
29. Centers for Disease Control and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects: 1983-1991. MMWR Morb Mortal Wkly Rep 1991 ;40:513-6.
30. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992;41:1-7.
31. US Food and Drug Administration. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996; 61:8781-97.
32. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257-61.
33. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6:219-26.
34. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. N Engl J Med 1999;341: 1485-90.
35. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285: 2981-6.
36. Erickson JD. Folic acid and prevention of spina bifida and anencephaly: 10 years after the U.S. Public Health Service recommendation. MMWR Recomm Rep 2002;51:1-3.
37. Persad VL, Van den Hof MC, Dubé JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 2002;167:241-5.
38. Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE. Association of neural tube defects and folic acid food fortification in Canada. Lancet 2002;360:2047-8.
39. Castilla EE, Orioli IM, López-Camelo JS, Dutra Mda G, Nazer-Herrera J; Latin American Collaborative Study of Congenital Malformations (ECLAMC). Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Genet A 2003;123:123-8.
40. De Wals P, Rusen ID, Lee NS, Morin P, Niyonsenga T. Trend in prevalence of neural tube defects in Quebec. Birth Defects Res A Clin Mol Teratol 2003;67:919-23.
41. De Wals P, Tairou F, Van Allen Ml, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007;357:135-42.
42. Centers for Disease Control and Prevention. Spina bifida and anencephaly before and after folic acid mandate: United States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep 2004;53:362-5.
43. Chen LT, Rivera MA. The Costa Rican experience: reduction of neural tube defects following food fortification programs. Nutr Rev 2004;62:S40-3.
44. Mills JL, Signore C. Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol 2004;70:844-5.
45. Lepez-Camelo JS, Orioli IM, da Graça Dutra M, et al. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A 2005;135:120-5.
46. Toriello HV; Professional Practice and Guidelines Committee, American College of Medical Genetics. Folic acid and neural tube defects. Genet Med 2005;7:283-4.
47. Bayston R, Russell A, Wald NJ, Hoffbrand AV. Folic acid fortification and cancer risk. Lancet 2007;370:2004.
48. Johnston RB Jr. Will increasing folic acid in fortified grain products further reduce neural tube defects without causing harm?: consideration of the evidence. Pediatr Res 2008; 63:2-8.
49. Brouwer I, Verhoef P. Folic acid fortification: is masking of vitamin B-12 deficiency what we should really worry about? Am J Clin Nutr 2007;86:897-8.
50. Kim Yl. Folic acid fortification and supplementation: good for some but not so good for others. Nutr Rev 2007;65: 504-11.
51. Smith AD. Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12. Am J Clin Nutr 2007;85:3-5.
52. Solomons NW. Food fortification with folic acid: has the other shoe dropped? Nutr Rev 2007;65:512-5.
53. Smith AD, Kim Yl, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008;87:517-33.
54. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. QJ Med 1993;86:703-8.
55. Adams MJ Jr, Khoury MJ, Scanlon KS, et al. Elevated mid-trimester serum methylmalonic acid levels as a risk factor for neural tube defects. Teratology 1995;51:311-7.
56. van der Put NMJ, Thomas CM, Eskes TK, et al. Altered folate and vitamin B12 metabolism in families with spina bifida offspring. QJM 1997;90:505-10.
57. Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase combined with low cobal-amin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-23.
58. Afman LA, van der Put NMJ, Thomas CM, Trijbels JM, Blom HJ. Reduced vitamin B12 binding by transcobalamin II increases the risk of neural tube defects. QJM 2001;94: 159-66.
59. Ray JG, Blom HJ. Vitamin B12 insufficiency and the risk of fetal neural tube defects. QJM 2003;96:289-95.
60. Suarez L, Hendricks K, Felkner M, Gunter E. Maternal serum B12 levels and risk for neural tube defects in a Texas-Mexico border population. Ann Epidemiol 2003;13:81-8.
61. Groenen PM, van Rooij IA, Peer PG, Gooskens RH, Zielhuis GA, Steegers-Theunissen RP. Marginal maternal vitamin B12 status increases the risk of offspring with spina bifida. Am J Obstet Gynecol 2004;191:11-7.
62. Gaber KR, Farag MK, Soliman SE, El-Bassyouni HT, El-Kamah G. Maternal vitamin B12 and the risk of fetal neural tube defects in Egyptian patients. Clin Lab 2007;53:69-75.
63. Ray JG, Wyatt PR, Thompson MD, et al. Vitamin B12 and the risk of neural tube defects in a folic-acid-fortified population. Epidemiology 2007;18:362-6.
64. Ray JG, Goodman J, O'Mahoney PR, Mamdani MM, Jiang D. High rate of maternal vitamin B12 deficiency nearly a decade after Canadian folic acid flour fortification. QJM 2008;doi: 10.1093/qjmed/hcn031.
65. Beaudin AE, Stover PJ. Folate-mediated one-carbon metabolism and neural tube defects: balancing genome synthesis and gene expression. Birth Defects Res C Embryo Today 2007; 81:183-203.
66. Cabrera RM, Hill DS, Etheredge AJ, Finnell RH. Investigations into the etiology of neural tube defects. Birth Defects Res C Embryo Today 2004;72:330-44.
67. Boyles AL, Hammock P, Speer MC. Candidate gene analysis in human neural tube defects. Am J Med Genet C Semin Med Genet 2005;135:9-23.
68. Blom HJ, Shaw GM, den Heijer M, Finnell RH. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 2006;7:724-31.
69. De Marco P, Merello E, Mascelli S, Capra V. Current perspectives on the genetic causes of neural tube defects. Neurogenetics 2006;7:201-21.
70. Padmanabhan R. Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom (Kyoto) 2006;46:55-67.
71. van der Linden IJM, Afman LA, Heil SG, Blom HJ. Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutr Soc 2006;65:204-15.
72. th edition. Philadelphia: Churchill Livingstone Elsevier, 2007;2648-60.
73. Kibar Z, Capra V, Gros P. Toward understanding the genetic basis of neural tube defects. Clin Genet 2007;71:295-310.
74. Barber RC, Shaw GM, Lammer EJ, et al. Lack of association between mutations in the folate receptor-alpha gene and spina bifida. Am J Med Genet 1998;76:310-7.
75. Heil SG, van der Put NMJ, Trijbels FJ, Gabreels FJ, Blom HJ. Molecular genetic analysis of human folate receptors in neural tube defects. Eur J Hum Genet 1999;7:393-6.
76. O'LearyVB, Mills JL, Kirke PN, et al. Analysis of the human folate receptor beta gene for an association with neural tube defects. Mol Genet Metab 2003;79:129-33.
77. Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, Quadros EV. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004;350:134-42.
78. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70:310-5.
79. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002;108:1-6.
80. De Marco P, Calevo MG, Moroni A, et al. Reduced folate carrier polymorphism (80A→G) and neural tube defects. Eur J Hum Genet 2003;11:245-52.
81. Morin I, Devlin AM, Leclerc D, Sabbaghian N, Halsted CH, Finnell R, Rozen R. Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol Genet Metab 2003;79:197-200.
82. Pei L, Zhu H, Ren A, Li Z, Hao L, Finnell RH, Li Z. Reduced folate carrier gene is a risk factor for neural tube defects in a Chinese population. Birth Defects Res A Clin Mol Teratol 2005;73:430-3.
83. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM 1995;88:763-6.
84. van der Put NMJ, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1.
85. van der Put NMJ, Eskes TK, Blom HJ. Is the common 677C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. QJM 1997;90:111-5.
86. Ou CY, Stevenson RE, Brown VK, et al. 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996;63: 610-4.
87. Christensen B, Arbour L, Tran P, Leclerc D, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999;84:151-7.
88. Stegmann K, Ziegler A, Ngo ET, et al. Linkage disequilibrium of MTHFR genotypes 677C/T-1298A/C in the German population and association studies in probands with neural tube defects (NTD). Am J Med Genet 1999;87:23-9.
89. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862-77.
90. Martínez de Villarreal LE, Delgado-Enciso I, Valdéz-Leal R, et al. Folate levels and N(5),N(10)-methylenetetrahydrofolate reductase genotype (MTHFR) in mothers of offspring with neural tube defects: a case-control study. Arch Med Res 2001;32:277-82.
91. Parle-McDermott A, Mills JL, Kirke PN, et al. Analysis of the MTHFR 1298A→C and 677C→T polymorphisms as risk factors for neural tube defects. J Hum Genet 2003; 48:190-3.
92. Rampersaud E, Melvin EC, Siegel D, et al. Updated investigations of the role of methylenetetrahydrofolate reductase in human neural tube defects. Clin Genet 2003;63:210-4.
93. Volcik KA, Shaw GM, Lammer EJ, Zhu H, Finnell RH. Evaluation of infant methylenetetrahydrofolate reductase genotype, maternal vitamin use, and risk of high versus low level spina bifida defects. Birth Defects Res A Clin Mol Teratol 2003;67:154-7.
94. van der Put NMJ, Gabreëls F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
95. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
96. Friedman G, Goldschmidt N, Friedlander Y, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 1999;129:1656-61.
97. Chango A, Boisson F, Barbé F, et al. The effect of 677C→T and 1298A→C mutations on plasma homocysteine and 5,10- methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000;83:593-6.
98. Richter B, Stegmann K, Röper B, Böddeker I, Ngo ET, Koch MC. Interaction of folate and homocysteine pathway genotypes evaluated in susceptibility to neural tube defects (NTD) in a German population. J Hum Genet 2001; 46:105-9.
99. Relton CL, Wilding CS, Laffling AJ, et al. Low erythrocyte folate status and polymorphic variation in folate-related genes are associated with risk of neural tube defect pregnancy. Mol Genet Metab 2004;81:273-81.
100. De Marco P, Calevo MG, Moroni A, et al. Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population J Hum Genet 2002;47:319-24.
101. Doolin MT, Barbaux S, McDonnell M, Hoess K, Whitehead AS, Mitchell LE. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet 2002;71:1222-6.
102. Guéant-Rodriguez RM, Rendeli C, Namour B, et al.Trans-cobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans. Neurosci Lett 2003;344:189-92.
103. Zhu H, Wicker NJ, Shaw GM, et al. Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab 2003;78:216-21.
104. Gos M, Sliwerska E, Szpecht-Potocka A. Mutation incidence in folate metabolism genes and regulatory genes in Polish families with neural tube defects. J Appl Genet 2004;45: 363-8.
105. van der Put NMJ, van der Molen EF, Kluijtmans LA, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. QJM 1997;90: 511-7.
106. Morrison K, Papapetrou C, Hol FA, Mariman EC, Lynch SA, Burn J, Edwards YH. Susceptibility to spina bifida; an association study of five candidate genes. Ann Hum Genet 1998;62:379-96.
107. Lucock M, Daskalakis I, Briggs D, Yates Z, Levene M. Altered folate metabolism and disposition in mothers affected by a spina bifida pregnancy: influence of 677c→t methylenetetrahydrofolate reductase and 2756a→g methionine synthase genotypes. Mol Genet Metab 2000;70:27-44.
108. Lucock M, Daskalakis I, Hinkins M, Yates Z. An examination of polymorphic genes and folate metabolism in mothers affected by a spina bifida pregnancy. Mol Genet Metab 2001;73:322-32.
109. Pietrzyk JJ, Bik-Multanowski M, Sanak M, Twardowska M. Polymorphisms of the 5,10-methylenetetrahydrofolate and the methionine synthase reductase genes as independent risk factors for spina bifida. J Appl Genet 2003;44:111-3.
110. O'Leary VB, Mills JL, Pangilinan F, et al. Analysis of methionine synthase reductase polymorphisms for neural tube defects risk association. Mol Genet Metab 2005;85:220-7.
111. Boyles AL, Billups AV, Deak KL, et al. Neural tube defects and folate pathway genes: family-based association tests of gene-gene and gene-environment interactions. Environ Health Perspect 2006;114:1547-52.
112. Hum DW, Bell AW, Rozen R, MacKenzie RE. Primary structure of a human trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydro-folate synthetase. J Biol Chem 1988;263:15946-50.
113. Hol FA, van der Put NMJ, Geurds MP, et al. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate- dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydro-folate synthetase) in patients with neural tube defects. Clin Genet 1998;53:119-25.
114. Brody LC, Conley M, Cox C, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/ formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002;71:1207-1 5.
115. Parle-McDermott A, Kirke PN, Mills JL, etal. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet 2006;14:768-72.
116. De Marco P, Merello E, Calevo MG, Mascelli S, Raso A, Cama A, Capra V. Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G>A polymorphism for neural tube defect risk. J Hum Genet 2006;51:98-103.
117. Heil SG, van der Put NMJ, Waas ET, den Heijer M, Trijbels FJM, Blom HJ. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001;73:164-72.
118. Woeller CF, Anderson DD, Szebenyi DME, Stover PJ. Evidence for small ubiquitin-like modifier-dependent nuclear import of the thymidylate biosynthesis pathway. J Biol Chem 2007;282:17623-31.
119. Lim U, Peng K, Shane B, et al. Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men J Nutr 2005;135:1989-94.
120. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the humangene for thymidylate synthase. Cell Struct Funct 1995;20: 191-7.
121. Kawakami K, Omura K, Kanehira E, Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999;19:3249-52.
122. Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001;7:4096-101.
123. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW. Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Cenet 2002;111: 299-302.
124. Wilding CS, Relton CL, Sutton MJ, Jonas PA, Lynch SA, Tawn EJ, Bum J. Thymidylate synthase repeat polymorphisms and risk of neural tube defects in a population from the northern United Kingdom. Birth Defects Res A Clin Mol Teratol 2004;70:483-5.
125. Brown KS, Kluijtmans LAJ, Young IS, et al. The thymidylate synthase tandem repeat polymorphism is not associated with homocysteine concentrations in healthy young subjects. Hum Genet 2004;114:182-5.
126. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9:1381-5.
127. Volcik KA, Shaw GM, Zhu H, Lammer EJ, Laurent C, Finnell RH. Associations between polymorphisms within the thymidylate synthase gene and spina bifida. Birth Defects Res A Clin Mol Teratol 2003;67:924-8.
128. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S. New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy? Am J Med Cenet A 2004;124:339-45.
129. van der Linden IJM, Nguyen U, Heil SG, et al. Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida. Mol Genet Metab 2007;91:98-103.
130. Parle-McDermott A, Pangilinan F, MillsJL, et al.The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet A 2007;143:1174-80.
131. Stanistawska-Sachadyn A, Brown KS, Mitchell LE, et al. An insertion/deletion polymorphism of the dihydrofolate reductase (DHFR) gene is associated with serum and red blood cell folate concentrations in women. Hum Genet 2008;123:289-95.